Tapur Targeted Agent And Profiling Utilization Registry (Tapur) Study
Posted Date: Jul 19, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
The primary objective of this study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. This study will consist of multiple arms and efficacy will be measured by objective response rate, which will be defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria.
Criteria:
Histologically-Proven Locally Advanced Or Metastatic Solid Tumor, Multiple Myeloma Or B Cell Non-Hodgkin Lymphoma Who Is No Longer Benefiting From Standard Anti-Cancer Treatment Or For Whom, In The Opinion Of The Treating Physician, No Such Treatment Is Available Or Indicated. Ecog Score Of 0-2. Absolute Neutrophil Count = 1.5 X 106/Μl. Hemoglobin > 9.0 G/Dl. Platelets > 75,000/Μl. Total Bilirubin < 2.0 Mg/ Dl, Except In Patients With Gilbert's Syndrome. Serum Creatinine = 1.5 × Uln Or Calculated Or Measured Creatinine Clearance = 50 Ml/Min/1.73 M2. No Patients Whose Disease Is Not Measurable Or Cannot Be Assessed By Radiographic Imaging Or Physical Examination. No Patients With Primary Brain Tumors Or Leptomeningeal Metastases.
Keywords:
Lymphoma, Myeloma, Tumors
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com